Sai Parenteral’s IPO
Sai Parenteral’s IPO Listing Day Performance
Sai Parenteral’s listed on BSE & NSE on 02 April 2026 at ₹405.00, a 3.32% premium over the issue price of ₹392. A retail investor allotted one lot of 38 shares gained ₹494 at the listing price.
Demand going into listing
| Subscribed overall | 1.08× |
| QIB | 1.73× |
| NII | 2.45× |
| Retail | 0.12× |
Market Sentiment
IPO Details
Day-wise Subscription (times subscribed)
| Category | Day 1 | Day 2 | Final | Final | Final | Final |
|---|---|---|---|---|---|---|
| QIB | 0.00x | 0.60x | 1.71x | 1.71x | 1.71x | 1.73x |
| NII | 0.15x | 1.01x | 2.36x | 2.36x | 2.36x | 2.45x |
| bNII > ₹10L | 0.21x | 1.49x | 3.43x | 3.43x | 3.43x | 3.56x |
| sNII 2-10L | 0.03x | 0.04x | 0.23x | 0.23x | 0.23x | 0.24x |
| Retail | 0.03x | 0.05x | 0.12x | 0.12x | 0.12x | 0.12x |
| Total | 0.04x | 0.41x | 1.05x | 1.05x | 1.05x | 1.08x |
Market Lot Size
IPO Reservation
Financial Analysis
Financial Data
Financial Performance
| Metric | 2023 | 2024 | 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 97.03 | 155.18 | 163.74 | 89.43 |
| Expense | 89.78 | 142.63 | 143.84 | 78.27 |
| Profit (PAT) | 4.38 | 8.42 | 14.43 | 7.76 |
| Total Assets | 133.96 | 268.10 | 272.39 | 376.24 |
Peer Comparison
| Company | EPS | P/E | Market Cap (Cr) |
|---|---|---|---|
| Sai Life Sciences Limited | 8.83 | 107.70 | 8 |
| InnovaCaptab Limited | 22.41 | 32.45 | 13 |
| Senores Pharmaceuticals Limited | 16.12 | 64.30 | 7 |
| Gland Pharma Limited | 42.40 | 44.71 | 8 |
| Industry Average | - | 62.29 | - |
Promoters & Holding Pattern
Promoters: Anil Kumar Karusala, Vijitha Gorrepati and Karusala Aruna
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 3,69,08,823 | 61.23% |
Strengths & Risks
- Solid profit margin — 8.8%.
- Strong return on equity — 15%.
- Mostly fresh capital — proceeds fund the company's growth, not an exit.
Our data checks haven't flagged a specific concern for Sai Parenteral’s — but that isn't a clean bill of health. Read the risk-factors section of the RHP, which lists company-specific risks our data can't capture.
From this issue's live data. Not investment advice — read the RHP.
Company Information
Sai Parenteral’s at a glance
From the company's description: “Sai Parenteral’s Ltd., founded in 2001, is one of the leading pharmaceutical companies focused on R&D and manufacturing of pharmaceutical products.”
Sai Parenteral’s is raising ₹409 crore through an IPO on the BSE and NSE mainboard. Of that, ₹285 crore is a fresh issue — new shares, with the money going to the company — and ₹124 crore is an offer for sale by existing shareholders, who keep those proceeds; 70% of the issue therefore reaches the business. Main stated uses of the fresh money: Capacity expansion and upgradation of manufacturing facilities (₹111 crore), Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed… (₹36 crore) and Working capital requirements (₹33 crore).
Revenue went from ₹97.03 crore in 2023 to ₹164 crore in 2025, up 69% over 2 years. Profit after tax went from ₹4.38 crore to ₹14.43 crore, a net margin of 8.8% in the latest year.
Written from the issue's offer-document figures shown on this page. Not investment advice.
Company Contact Information
Sai Parenteral’s Ltd., Plot No 39, 5th floor, Lavanya Arcade, Jayabheri Enclave, Gachibowli, K.V.Rangareddy, Seri Lingampally, Hyderabad, Telangana, 500032
Objects of the Issue
| Purpose | Amount (Cr) |
|---|---|
| Capacity expansion and upgradation of manufacturing facilities | 110.80 |
| Establishment of a new R&D Centre; | 18.02 |
| Repayment / prepayment of certain outstanding borrowings | 20.00 |
| Working capital requirements | 33.00 |
| Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and | 36.00 |
| General corporate purposes | - |
Resources & Documents
Anchor Investors
IPO Documents
Draft Red Herring ProspectusSai Parenteral’s IPO - Quick Take
Sai Parenteral’s has set a price band of Rs 372–Rs 392 per share for an issue size of Rs 409 crore. The stock listed with a 3.32% gain versus its issue price on April 02, 2026.
The issue is promoted by Anil Kumar Karusala, Vijitha Gorrepati and Karusala Aruna with Arihant Capital Markets Ltd. acting as lead manager. Net proceeds will primarily be used towards capacity expansion and upgradation of manufacturing facilities (Rs 111 crore) and establishment of a new R&D Centre; (Rs 18 crore).
On fundamentals, the company is posting revenue growth of 5.5%, a profit margin of 8.8%, return on equity of 15.1% in its most recent reported period. Listed peers in this segment include InnovaCaptab Limited (P/E 32.45x, market cap Rs 13 crore) and Sai Life Sciences Limited (P/E 107.70x, market cap Rs 8 crore) — useful reference points when evaluating the issue's pricing relative to where the broader sector is trading.
On our data-signal score, the combined signals for this issue currently read weak — several key indicators are reading below average. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Sai Parenteral’s IPO: Lead Manager & Registrar Track Record
How the firm running this issue and its registrar have fared on the other IPOs we track. Each firm's figures leave out Sai Parenteral’s itself, so they describe what came before it.
- Sai Parenteral’s listed at +3.3% on day one; the median of 113 listings was +7% (better than 37% of them).
- Subscribed 1.08x against a median of 20.56x across 111 issues (higher than 3%).
- Average listing-day move across all 114 Mainboard listings we track: +13.6%.
| Firm | Other IPOs | Listed at / above issue | Avg move | Median |
|---|---|---|---|---|
| Arihant Capital Markets Ltd. Lead manager | First we track | — | — | — |
| Bigshare Services Pvt. Ltd. Registrar | 61 18 MB · 43 SME | 67% 41 of 61 | Check allotment → | |
A SEBI-registered merchant banker that runs the issue: due diligence, drafting the offer document, setting the price band with the company, and marketing the IPO to investors.
Finalises the basis of allotment, credits shares to demat accounts, releases blocked funds for unsuccessful bids and handles investor queries about the issue.
Listing-day move = exchange opening price vs issue price (band ceiling where the final price isn't recorded). Counts cover IPOs we track only. Past listings don't predict this one; this is not investment advice.
Frequently Asked Questions
Sai Parenteral’s IPO GMP — What It Means
No grey market premium was recorded for Sai Parenteral’s before it listed.
See the full Sai Parenteral’s GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
Same sector or same stage as Sai Parenteral’sNo comments yet. Be the first to share your opinion!